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ABSTRACT (222) 20 
Objectives 21 
To investigate serum biomarkers, tartrate resistant acid phosphatase 5b (TRAcP5b) and 22 
cathepsin K, indicative of osteoclastic bone resorption, and their relationship to pain and pain 23 
change in knee osteoarthritis (OA).  24 
Methods 25 
Sera and clinical data were collected from 129 people (97 with 3-year follow-up) with knee 26 
OA from the Prediction of Osteoarthritis Progression (POP) cohort. Knee OA-related 27 
outcomes in POP included: WOMAC pain, NHANES I (pain, aching and stiffness), 28 
subchondral sclerosis, and radiographically determined tibiofemoral and patellofemoral OA. 29 
Two putative osteoclast biomarkers were measured in sera: TRAcP5b and cathepsin K. 30 
Medial tibia plateaux were donated at knee arthroplasty for symptomatic OA (n=84) or from 31 
16 post mortem controls from the Arthritis Research UK (ARUK) Pain Centre joint tissue 32 
repository. Osteoclasts were stained for TRAcP within the subchondral bone of the medial 33 
tibia plateaux.  34 
Results 35 
Serum TRAcP5b activity, but not cathepsin K-immunoreactivity, was associated with density 36 
of TRAcP-positive osteoclasts in the subchondral bone of medial tibia plateaux. TRAcP-37 
positive osteoclasts were more abundant in people with symptomatic OA compared to 38 
controls. Serum TRAcP5b activity was associated with baseline pain and pain change.   39 
Conclusions 40 
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Our observations support a role for subchondral osteoclast activity in the generation of OA 41 
pain. Serum TRAcP5b might be a clinically relevant biomarker of disease activity in OA. 42 
 43 
Key words: TRAcP5b, Subchondral bone, Biomarker, Osteoarthritis Pain, Osteoclast 44 
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INTRODUCTION 46 
Pain is the reason for most osteoarthritis (OA)-related medical visits. OA knee pain 47 
substantially impacts quality of life and is a key determining factor for loss of joint function 1. 48 
Available drug treatments focus on analgesia, but often do not have sustained benefit and 49 
many patients experience unwanted side effects 2.  50 
Although OA affects articular cartilage, it is increasingly recognised as a disease of the whole 51 
joint. Changes in subchondral bone are key in the pathogenesis of knee OA, and associated 52 
with knee pain 3 and radiographic progression 4. Bone remodelling and increased pain 53 
mediators (cyclooxygenase 2, substance P, TNF-α) in the subchondral bone might occur 54 
before overt OA cartilage degeneration 5. Subchondral bone is densely innervated by sensory 55 
nerves 6, and might be a key source of OA pain.  56 
Animal models of OA and imaging studies in man support associations between pain and 57 
subchondral structural pathology 7-9. In particular, increased osteoclast activity indicative of 58 
subchondral bone turnover might be associated with OA and pain 7, 10. Osteoclasts are 59 
multinucleated giant cells responsible for homeostatic bone resorption that release enzymatic 60 
markers, including tartrate resistant acid phosphatase (TRAcP) and cathepsin K. TRAcP, 61 
originally called type 5 acid phosphatase, can be expressed both by osteoclasts and 62 
macrophages 11; it was identified in human serum and separated electrophoretically into two 63 
distinct bands: 5a and 5b. Electrophoretic studies suggest band 5b (TRAcP5b) is derived from 64 
osteoclasts and 5a from macrophages 12. Cathepsin K, a cysteine protease, has been 65 
implicated in OA pathogenesis, largely because of its upregulation in areas of cartilage 66 
damage and resorbed bone 13, 14. Roles of cathepsin K in the initial stages of bone resorption 67 
have led to it becoming a target for novel therapeutic approaches for diseases such as 68 
osteoporosis, where reduced bone resorption can increase bone mineral density and reduce 69 
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fracture risk 15. Circulating TRAcP5b activity and cathepsin K are reduced in clinical trials 70 
during bisphosphonate treatment 16, 17.  71 
Bone and cartilage biomarkers have been investigated in OA structural progression 18, 19, and 72 
some circulating inflammation biomarkers have been associated with OA pain, including C 73 
reactive protein (CRP), tumour necrosis factor (TNF)-α, interleukin (IL)-6 20 and interleukin 74 
(IL)-1β 21. One study reports concentrations of N-telopeptide of type I collagen (uNTX-I) 75 
being significantly increased in people with OA knee pain (VAS score) independent of 76 
radiographic severity 22. However, validated biomarkers of subchondral osteoclast activity 77 
associated with OA pain, or pain progression, have yet to be reported. 78 
We hypothesised that biomarkers which reflect subchondral osteoclast activity, will be 79 
associated with OA pain, and might be useful in predicting pain progression in OA. The 80 
objectives of this study were to identify and validate serum biomarkers of subchondral 81 
osteoclast activity in people with symptomatic knee OA and to evaluate the association of 82 
these markers with OA pain, structural severity, and progression.  83 
 84 
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PATIENTS AND METHODS 86 
Data reports a cross-sectional, case-control, cohort study.  87 
Participants. 129 participants from the Prediction of Osteoarthritis Progression (POP) cohort 88 
19 and knee tissue from 100 subjects from the Arthritis Research UK (ARUK) Pain Centre 89 
joint tissue repository 23 were available (Table 1). Included participants met the American 90 
College of Rheumatology (ACR) criteria for symptomatic OA 24. Samples from 129 of the 91 
POP cohort were available at baseline and from 97 at 3-year follow up. Participants in the 92 
POP cohort who had unilateral total knee replacement (TKR) surgery before baseline blood 93 
and data collection were excluded, and those who had TKR before follow up were excluded 94 
from longitudinal analyses. Cases from the joint tissue repository had knee tissue taken at 95 
TKR surgery for symptomatic OA (n = 84), or post mortem (PM) (n = 16) from people who 96 
had not sought help for knee pain during the last year of life (asymptomatic control group). 97 
Sixteen cases from each of the TKR and PM groups were matched for macroscopic 98 
chondropathy scores, age and gender. Macroscopic chondropathy was scored by a single 99 
observer as previously described 25, taking account of severity (graded from 0 (normal 100 
unbroken surface) to 4 (subchondral bone exposure)) and extent (percentage of area involved 101 
by each grade) to calculate a chondropathy score from 0 – 100. Scores for all 4 compartments 102 
(medial and lateral tibial plateaux and femoral condyles) were summed to give a total 103 
chondropathy score from 0-400. Participants were excluded if they had specific bone disease 104 
known to affect bone turnover (e.g. Paget’s disease of the bone, osteomalacia), or non-OA 105 
diagnoses as a cause of knee pain (e.g. rheumatoid arthritis, acute gout), but not according to 106 
medication use (Table 1). Cases with self-reported osteoporosis were also included (Table 1). 107 
(Insert table I here) 108 
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Imaging. Postero-anterior weight-bearing knee radiographs were obtained as previously 109 
described 25-27. Radiographs of the POP cohort were scored by observers blinded to patient 110 
details for Kellgren-Lawrence (K/L) grade (0-4) 28 and individual radiographic features of 111 
OA including joint space narrowing (JSN 0-3), osteophytes (OST 0-3), subchondral sclerosis 112 
(0 or 1) and patellofemoral OA (0-3) using a standardized atlas 29. Total scores were summed 113 
scores for both knees (right + left) and compartments (tibia – medial, lateral; femur – medial, 114 
lateral) 19. Knee radiographs for cases providing joint tissues at TKR were scored using an 115 
atlas of line drawings of medial and lateral JSN and OST 30. JSN (range 0–6) and OST (range 116 
0–12) scores were summed to provide a total radiographic OA severity score for each knee 117 
(range 0–18). Radiographs were not available for post mortem cases. 118 
Scintigraphic imaging of knees and whole body was performed as previously described 19, 27. 119 
The radiotracer methylene-diphosphonate labelled with technetium-99m was administered 2 120 
hours prior to imaging. Sixteen joint sites were scored semiquantitatively by 2 experienced 121 
observers blinded to patient detail, on a scale of 0–3, where 0 = normal to 3 = intense. The 122 
scores were summed for each joint site. Scored sites included knees, shoulders, elbows, 123 
wrists, hands, hips, sacroiliac joints, ankles, forefeet, first metatarsophalangeal joints, 124 
sternoclavicular joints, acromioclavicular joints, the sternomanubrial joint, the cervical spine, 125 
the thoracic spine, and the lumbar spine. 126 
Pain assessment. In the POP cohort, pain was assessed using the Likert pain scale of the 127 
Western Ontario and McMaster Universities Osteoarthritis index (WOMAC-A) 31. It consists 128 
of 5 summed items (pain on walking, stair climbing, nocturnal, rest and weight bearing) 129 
scored from 0 = none, 1 = mild, 2 = moderate, 3 = severe and 4 = extreme, to give a total 130 
subscore ranging from 0-20. Knee symptoms were also ascertained by the National Health 131 
and Nutrition Examination Survey (NHANES) I criterion 32 of pain, aching or stiffness on 132 
most days of any one month in the last year; for subjects answering yes, symptoms were 133 
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quantified as mild, moderate, or severe, yielding a total score of 0-3 for each knee. Change 134 
scores were calculated separately for WOMAC pain and NHANES I pain as follow-up score 135 
minus baseline score, summed across both knees, and used to define pain worsening or 136 
improvement in participants over 3 years as previously published 19. Pain scores were not 137 
available for ARUK Pain Centre joint tissue repository cases, and sera were not available for 138 
PM cases. 139 
Biomarker quantification. TRAcP5b activity and cathepsin K concentrations were analysed 140 
in serum stored at -80°C from participants in the POP cohort and from TKR patients in the 141 
ARUK joint repository group. Experimenter was blinded to patient details. Both biomarkers 142 
were measured in undiluted serum by enzyme-linked immunosorbent assay (ELISA) 143 
according to the manufacturer’s protocol. TRAcP5b activity (U/L) was measured using a 144 
Bone TRAP® (TRAcP5b) ELISA (immunodiagnostic systems – IDS). Concentrations of 145 
cathepsin K (pg/ml) were measured using a human cathepsin K (cath-K) ELISA 146 
(CUSABIO). Inter-assay coefficient of variation (CVs) for TRAcP5b was 0.89% and 147 
cathepsin K; 9.52%. Twenty-two samples were below the lower limit of detection (LLOD) 148 
for TRAcP5b (0.5U/L). One sample was below the LLOD for cathepsin K (7.5pg/ml). A 149 
value equal to one half the LLOD was imputed for these samples for the purposes of 150 
statistical analyses. 151 
TRAcP positive osteoclast density. Mid-coronal sections (5µm) of the middle one-third of 152 
the medial tibial plateau (an important weight bearing area characteristically affected by OA) 153 
were fixed in neutral buffered formalin and then decalcified in 10% EDTA in 10mM Tris 154 
buffer (pH 6.95; at 4°C) prior to embedding in paraffin wax. Sections were stained for 155 
TRAcP-positive osteoclasts in two sections per case from the middle one-third of the medial 156 
tibial plateau. Samples were deparaffinized in xylene, rehydrated in serial alcohol and 157 
distilled water, and recalcified in a solution containing 1mM CaCl2 and 1mM MgCl2 in PBS 158 
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overnight. TRAcP was stained using a commercially available kit (#387A Sigma-Aldrich, 159 
UK) following the manufacturer’s protocol. The numbers of TRAcP positive osteoclasts 160 
within the subchondral bone area were counted manually using a Zeiss Axioscop-50 161 
microscope (Carl Zeiss Ltd, Welwyn Garden City, UK) at 20x magnification to a depth of 162 
400µm from the calcified cartilage. The scorer was blind to patient details. The number of 163 
osteoclasts was divided by the length of the subchondral bone to give an osteoclast density 164 
expressed as TRAcP positive cells per mm 33. 165 
Statistical analysis. Data were analysed using Statistical package for the Social Sciences 166 
v.22 (SPSS Inc., Chicago, Illinois, USA). Pilot studies were carried out prior to main study 167 
for power calculations for sample size. Between group (TKR vs. PM, with vs. without 168 
osteoporosis) comparisons for TRAcP-positive osteoclasts were tested using the Mann-169 
Whitney U test. Biomarker data were natural log (Ln) transformed to obtain a normal 170 
distribution for use in all analyses. Shapiro-Wilks test confirmed that ln transformed 171 
biomarker data did not significantly diverge from normality. Univariable and multivariable 172 
linear regressions were used for all association analyses, including between bone biomarkers 173 
and TRAcP-positive osteoclast density, between bone biomarkers and OA outcomes 174 
(WOMAC pain, NHANES I pain, subchondral sclerosis, patellofemoral OA, JSN, 175 
osteophyte, and KL grade) or total burden of OA at the knee and other joints at baseline 176 
based on scintigraphy (cross-sectional study). Univariable and multivariable linear 177 
regressions were used to assess associations of baseline TRAcP5b and cathepsin K with 178 
change in pain (WOMAC and NHANES I) over the 3-year follow up in the POP cohort 179 
(longitudinal study). A one-factor principal component analysis (PCA) was performed for the 180 
joints assessed by bone scintigraphy as previously described 19. This produced a factor that 181 
explained 20% of the variance in the whole body bone scintigraphy data. This factor, 182 
reflecting bone formation 34, 35 was assessed for association with the osteoclast related 183 
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biomarkers. All parameter estimates were adjusted for OA risk factors (age, sex, BMI) and, 184 
where appropriate, for bisphosphonate use because bisphosphonates are known to inhibit 185 
osteoclast activity. In addition to beta coefficients, marginal effects for pain outcomes are 186 
presented where statistically significant associations were demonstrated after adjustments. 187 
Numerical and graphical data are presented as mean ± 95% confidence interval to denote 188 
statistical uncertainty of estimates between groups, whereas mean ± SD is used for 189 
descriptive variables. P < 0.05 was considered statistically significant.  190 
 191 
 192 
  193 
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RESULTS 194 
Demographics of participants 195 
The 129 participants from the POP cohort with symptomatic knee OA at baseline comprised 196 
72% females with an overall mean ± SD age of 64 ± 11 years and mean ± SD BMI of 31.4 ± 197 
6.6 kg/m2 (Table 1). A 3-year follow up of 97 participants from the POP cohort included 72% 198 
females with an overall mean ± SD age of 67 ± 11 years and mean ± SD BMI of 31.6 ± 6.7 199 
kg/m2. The mean ± SD baseline concentrations of TRAcP5b and cathepsin K for these 200 
participants were 0.8 ± 0.4U/L and 170.7 ± 110.7pg/ml, respectively. Mean (SD) baseline 201 
WOMAC and NHANES I pain scores were 5.2 ± 3.2 and 2.9 ± 1.2, respectively. Pain 202 
change, defined as follow-up minus baseline score in the POP participants, was a mean (95% 203 
CI) of 0.13 (-0.85-1.1) and -0.3 (-0.6-0.0008) for WOMAC and NHANES I pain, 204 
respectively. 205 
ARUK Pain Centre joint repository knee tissue and sera, were obtained at TKR from 84 206 
people (57% female) who had symptomatic knee OA, with an overall mean ± SD age of 66 ± 207 
10 years and mean ± SD BMI of 31.3 ± 6.8 kg/m2 (Table 1). Knee tissues were obtained at 208 
PM from 16 subjects (56% female) who did not seek help for knee pain in the last year of 209 
their life (mean ± SD age 69 ± 12 years). The mean ± SD baseline concentrations of 210 
TRAcP5b and cathepsin K in the TKR subjects were 3.35 ± 1.48U/L and 9.54 ± 18.1 pg/ml, 211 
respectively. 212 
Associations between osteoclast density in OA subchondral bone, serum osteoclast 213 
biomarkers, and symptomatic knee OA 214 
To investigate whether the biomarkers TRAcP5b and cathepsin K are serum markers of 215 
subchondral osteoclast activity, we assessed their associations with TRAcP-positive 216 
osteoclast density in OA subchondral bone from patient samples (n=68) obtained at TKR for 217 
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knee OA. TRAcP-positive osteoclasts were identified in OA subchondral bone samples at a 218 
mean (95% CI) density of 1.5 (0.95 – 2) mm-1. TRAcP5b and cathepsin K were detectable in 219 
the serum of the TKR group by immunoassay. Serum TRAcP5b was associated with density 220 
of TRAcP-positive osteoclasts, independent of age, sex, and BMI. In contrast, serum 221 
cathepsin K was not statistically significantly associated with TRAcP-positive osteoclast 222 
density (Table 2). In the POP cohort, as expected neither TRAcP5b nor cathepsin K was 223 
statistically significantly associated with new bone formation, as assessed by namely knee or 224 
total body bone scintigraphy scores (supplementary Table 1). 225 
Asymptomatic (PM) and symptomatic (TKR) chondropathy groups (n = 16), matched for 226 
macroscopic chondropathy scores mean (95% CI); (200 (186 – 215) and 209 (196 – 221), 227 
respectively (p = 0.38)) were assessed for TRAcP-positive osteoclasts. TRAcP-positive 228 
osteoclasts in subchondral bone were significantly more abundant in people with 229 
symptomatic knee OA (mean density 1.0 (0.50 – 1.5) mm-1) compared to the asymptomatic 230 
PM controls (0.16 (0.04 – 0.28) mm-1), p = 0.001 (Figure 1 and Figure 2A & B). 231 
(Insert table II here) and (Figure 1 and 2) 232 
Association of bone biomarkers with OA pain and structural severity.  233 
In a cross-sectional, baseline serum TRAcP5b in the POP cohort (n=129) was associated with 234 
WOMAC pain score (β = 1.24, 95%CI 0.21 - 2.26; p = 0.02) (Table 3) and subchondral 235 
sclerosis (β = 0.35, 95%CI 0.07 - 0.63; p = 0.02) (Table 4), even after adjusting for age, sex, 236 
and BMI. This association persisted after adjusting for bisphosphonate use. Based on 237 
marginal effect sizes, the mean baseline TRAcP5b levels would need to be 2.3-fold to 2.8-238 
fold higher to predict a 1unit higher baseline WOMAC pain score. Baseline serum TRAcP5b 239 
activity was not significantly different in participants who reported osteoporosis compared to 240 
those who did not (p = 0.47). Baseline serum TRAcP5b was also associated with NHANES I 241 
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pain score (Table 3), and baseline serum cathepsin K in the POP cohort was associated with 242 
radiographic severity of patellofemoral OA (Table 4), but statistical significance was lost 243 
after adjusting for age, sex, and BMI.  244 
 (Insert table III and IV here) 245 
Association of baseline TRAcP5b with OA pain change  246 
To evaluate the predictive capability of TRAcP5b and cathepsin K for change in OA pain 247 
(WOMAC and NHANES I), we assessed the associations of bone biomarkers at baseline with 248 
change in pain scores during a 3-year follow up (n = 97). Baseline TRAcP5b was associated 249 
with pain change as evaluated by the NHANES I pain questionnaire (β = 0.69, 95%CI 0.19 – 250 
1.20; p = 0.008) after adjustment for age, sex, BMI, and baseline NHANES I pain, but not 251 
with WOMAC pain (β = 0.71, 95%CI -0.90 – 2.33; p = 0.38) (Table 5). Associations between 252 
baseline serum TRAcP5b and change in pain (NHANES I) remained statistically significant 253 
after adjusting for bisphosphonate use (Table 5). Based on marginal effect sizes, the mean 254 
baseline levels of TRAcP5b would need to be 5.3-fold to 11-fold higher to predict an 255 
additional 1unit increase in NHANES I pain score between baseline and follow up. Baseline 256 
cathepsin K was not associated with pain change (either WOMAC or NHANES I) (Table 5). 257 
Based upon our regression findings, Although the magnitude of the association between 258 
TRAcP5b and WOMAC pain was similar to NHANES I, there were no statistically 259 
significant relationships. 260 
(Insert table V here) 261 
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DISCUSSION 263 
In the context of knee OA, increased density of TRAcP-positive osteoclasts was associated 264 
with knee symptoms. Serum concentrations of TRAcP5b, which we show to be a marker of 265 
subchondral osteoclast numbers, was statistically significantly associated with OA pain and 266 
pain change. These data provide important new evidence that subchondral bone remodelling 267 
contributes to OA. Moreover, serum TRAcP5b may have potential as a biomarker to assist in 268 
the selection of patients who could benefit from treatments targeting bone resorption in OA. 269 
Subchondral bone changes are an integral part of the OA pathology. Bone remodelling at 270 
joint margins leads to osteophyte formation, and subchondral uptake of a radiotracer 271 
(methylene-diphosphonate labelled with technetium-99m) detected by scintigraphy, reflecting 272 
bone formation, has previously been associated with both radiographic OA disease 273 
progression and with knee pain 27, 36, 37. Bone remodelling requires osteoclast activity. We 274 
tested whether osteoclast enzymes released during bone resorption, cathepsin K and 275 
TRAcP5b 38, 39, could serve as markers of subchondral osteoclast activity. Our data, linking 276 
osteoclast activity, as reflected by serum TRAcP5b, with OA pain provide a clear biological 277 
mechanism that could explain the reported analgesic benefit of anti-resorptives such as 278 
bisphosphonates in human 40, 41 and rodent OA 7. We also observed at baseline, an association 279 
of serum TRAcP5b with subchondral bone sclerosis as well as with WOMAC pain scores, 280 
further suggesting a link between subchondral bone remodelling and pain generation in OA. 281 
Other cartilage and bone biomarker studies have reported on associations with structure and 282 
structural progression in OA 42 , but not with OA pain progression. In the current study, we 283 
report strong associations between baseline serum TRAcP5b and subsequent change in 284 
symptoms measured by NHANESI. 285 
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Increased numbers of TRAcP-positive osteoclasts in subchondral bone have been reported in 286 
human 33 and rodent 43 OA, and preclinical and imaging studies report possible involvement 287 
of osteoclasts in osteoarthritic pain 7, 10. In the current study, we show that in samples 288 
matched for chondropathy, osteoclast density was higher in people who sought treatment for 289 
knee pain (TKR) compared to those who did not (PM), indicating that osteoclast densities 290 
might contribute to OA symptoms independent of OA structural severity. In addition, by 291 
altering joint shape and loading, osteoclast-mediated subchondral bone remodelling might 292 
contribute to further cartilage damage.  293 
Osteoclasts are derived from monocytes, which originate within the bone marrow. Activated 294 
osteoclasts release both cathepsin K and TRAcP5b during the course of bone resorption, 295 
although only serum TRAcP5b, and not cathepsin K, was associated with subchondral 296 
osteoclast numbers in the current study. The statistically significant association between 297 
TRAcP5b serum levels and osteoclast numbers suggest that a high proportion of circulating 298 
TRAcP5b might originate from subchondral bone during OA disease activity, whereas 299 
circulating cathepsin K may be derived from additional sources (e.g. chondrocytes) 33, 44. 300 
Further work would require investigating serum concentrations of cathepsin K with 301 
chondrocytes. 302 
TRAcP5b has two enzymatic roles after its release from osteoclasts. It acts as a phosphatase 303 
at acidic pH, and also as a generator of reactive oxygen species (ROS) at neutral pH. ROS 304 
may participate in the breakdown of endocytosed bone matrix products in resorbing 305 
osteoclasts 45 and be involved in pain generation in OA 46. In the current study, we report for 306 
the first time, statistically significant associations of serum TRAcP5b with WOMAC pain 307 
scores in OA. Other studies have shown inflammatory biomarkers, C-reactive protein (CRP), 308 
tumour necrosis factor (TNF)-α, interleukin (IL)-6 20 and interleukin (IL)-1β 21 associated 309 
with OA pain. Anti-cytokine treatments have been tested in clinical trials for OA pain, but 310 
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lack of clinically important improvements over placebo might indicate that these molecules 311 
mediate OA pain only alongside other factors, or in subgroups of patients 47, 48. 312 
High concentrations of serum TRAcP5b have been detected in diseases characterized by 313 
increased osteoclastic activity such as Paget’s disease, haemodialysis, primary 314 
hyperparathyroidism 49 and malignancies involving bone resorption, for example breast 315 
cancer with bone metastases 39. In the current study, patients with other bone diseases were 316 
excluded and parameter estimates adjusting for bisphosphonates did not alter statistically 317 
significant associations observed between serum TRAcP5b, structural pathology, pain, and 318 
pain change in OA. Histological examination of the subchondral bone did not reveal 319 
malignant infiltration in any case in our current study, but we do not disregard the possibility 320 
of systemic effects of malignancy. Furthermore, concentrations of serum TRAcP5b were not 321 
different in participants with or without osteoporosis suggesting that relationships of 322 
TRAcP5b activity to symptomatic knee OA were independent of the presence of 323 
osteoporosis. Serum TRAcP5b concentrations were reported to be decreased following 324 
administration of the bisphosphonate alendronate in postmenopausal women with 325 
osteoporosis 16. From studies that show analgesic effects of bisphosphonates, and with 326 
findings from the current study, we suggest that bisphosphonates might reduce pain in OA by 327 
reducing osteoclast activity.  328 
OA has traditionally been viewed as a disorder of the tibiofemoral joint (TFJ), but the 329 
patellofemoral joint (PFJ) is one of the most commonly affected compartments in OA and 330 
also an important source of pain in OA 50. The association observed between serum cathepsin 331 
K and patellofemoral but not tibiofemoral OA suggests that different biomarkers might 332 
reflect OA disease activity in different joint compartments of the knee. Patellofemoral OA 333 
with cartilage loss of the patella and trochlea groove is reported in about half of patients 334 
diagnosed with knee OA 51. 335 
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Both TRAcP5b and cathepsin K are released by osteoclasts and are involved in bone 336 
resorption during bone turnover. Neither serum TRAcP5b nor cathepsin K was associated in 337 
the current study with bone scintigraphy scores; this underscores the specificity of these 338 
markers for bone resorption rather than bone formation. In another study, alpha - C-339 
telopeptide of type I collagen [α-CTX], a marker of degradation of newly formed bone, was 340 
associated with bone scintigraphy 19. Serum biomarkers of osteoclast activity, such as 341 
TRAcP5b, reflect the specific domain of bone resorption and thereby provide distinct and 342 
complementary information to that provided by other bone turnover markers 34, 35.  343 
Our study is necessarily subject to a number of limitations. There were no knee tissues 344 
available from the participants of the POP cohort so we could not directly correlate TRAcP 345 
osteoclasts to TRAcP5b serum concentrations, pain or subchondral sclerosis in this cohort. 346 
Likewise, there were no serum samples available for the asymptomatic chondropathy group 347 
(PM) so circulating TRAcP5b could not be quantified. We also assumed that people in the 348 
PM group had experienced less pain than the patients in the symptomatic chondropathy group 349 
(TKR), since to the best of our knowledge, they had not sought medical attention for knee 350 
pain during their last year of life. In the current study, we investigated the association of 351 
TRAcP-positive osteoclasts from tibia samples to serum TRAcP5b. Osteoclast activity in the 352 
femoral condyles might further contribute to serum TRAcP5b 52. In addition, lack of 353 
statistically significant association for most of the analyses with cathepsin K, and between 354 
cathepsin K and TRAcP5b might be due to limitations in the sensitivity of the cathepsin K 355 
assay used. 356 
Our findings identify serum TRAcP5b as a marker of subchondral osteoclast activity and 357 
suggest its potential utility as a biomarker for OA pain and pain change. TRAcP5b deserves 358 
further investigation as a biomarker of bone remodelling to aid in identifying people for 359 
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whom osteoclast activity contributes to OA pain, and who might be particularly responsive to 360 
analgesic and disease modification potential of anti-resorptive agents. 361 
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Figure 1 553 
TRAcP positive osteoclasts were statistically significantly higher in people with symptomatic 554 
OA (TKR) compared to PM controls who also presented with chondropathy but did not seek 555 
help for knee pain. Data indicate mean ± SEM for n = 16 per group. Differences between 556 
groups were analysed using a Mann Whitney-U test. TKR – total knee replacement, PM – 557 
post mortem. 558 
Figure 2 559 
TRAcP positive osteoclasts in the subchondral bone of OA patients at TKR. 560 
TRAcP positive osteoclasts stained in sections from the medial tibial plateau show severely 561 
eroded cartilage (red arrow - A). TRAcP staining showed active multinucleated osteoclasts 562 
(purple) within bone marrow spaces (B) and in areas of fibrovascular replacement (A). 563 
TRAcP positive osteoclasts on the edge of the bone signify sites of bone resorption and a 564 
resorption cavity (asterisk) as evidence of bone remodelling. CC – calcified cartilage, FT – 565 
fibrovascular tissue. Scale bars = 100µm. 566 
 567 
  568 
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Table I 569 
Demographics of patient study groups 570 
 Prediction of Osteoarthritis 
Progression (POP) cohort 
Arthritis Research UK (ARUK) 
Pain Centre joint repository 
Number Baseline; 129 Follow up; 97 TKR; 84a PM; 16 
Age (mean ± SD 
years) 
64 ± 11  67 ± 11 66 ± 10  69 ± 12 
Female (%) 72  72  57 56 
BMI (mean ± 
SD kg/m2) 
31.4 ± 6.6 31.6 ± 6.7 31.3 ± 6.8 n/a 
Osteoporosis 
(%) 
17 16 0 0 
Bisphosphonate 
use (%) 
11 9 0 0 
a Matched TKR cases (n=16) were a subgroup of the total TKR cases used. TKR; total knee 571 
replacement, PM; post mortem. 572 
 573 
 574 
  575 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
29 
 
Table II 576 
Relationship of serum biomarkers to TRAcP positive osteoclast density 577 
 TRAcP5b Cathepsin K 
 β (95% CI) P β (95% CI) P 
TRAcP 
osteoclast 
density 
0.74 (0.04 to 1.44) 0.04 0.13 (-0.26 to 0.52) 0.50 
TRAcP 
osteoclast 
density† 
0.74 (0.01 to 1.47) 0.047 0.12 (-0.29 to 0.53) 0.57 
†Adjusted for baseline age, sex, BMI. 578 
 579 
 580 
Table III 581 
Relationship of serum biomarkers of osteoclast activity to OA pain 582 
 TRAcP5b Cathepsin K 
 β (95% CI) P β (95% CI) P 
WOMAC pain 1.64 (0.58 to 2.71) 0.003 -0.05 (-0.87 to 0.78) 0.91 
WOMAC pain† 1.24 (0.21 to 2.26) 0.02 -0.21 (-0.99 to 0.57) 0.60 
WOMAC pain†¶ 1.28 (0.24 to 2.32) 0.02 -0.21 (-0.99 to 0.57) 0.60 
NHANES I pain 0.45 (0.06 to 0.84) 0.02 0.15 (-0.14 to 0.45) 0.31 
NHANES I 
pain† 
0.26 (-0.10 to 0.62) 0.16 0.10 (-0.17 to 0.37) 0.48 
NHANES I 
pain†¶ 
0.27 (-0.10 to 0.63)  0.15 0.10 (-0.17 to 0.37) 0.48 
†Adjusted for age, sex, BMI and ¶ for bisphosphonates. WOMAC pain marginal effect sizes 583 
(fold increase in TRAcP5b associated with 1 unit higher WOMAC pain score); 2.3, †2,8 and 584 
¶2.7. 585 
586 
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Table IV 587 
Relationship of serum biomarkers of osteoclast activity to structural OA features  588 
 TRAcP5b Cathepsin K 
 β (95% CI) P β (95% CI) P 
Subchondral 
sclerosis 
0.32 (0.04 to 0.59) 0.03 -0.01 (-0.22 to 0.20) 0.92 
Subchondral 
sclerosis† 
0.35 (0.07 to 0.63) 0.02 -0.01 (-0.23 to 0.20) 0.91 
Subchondral 
sclerosis†¶ 
0.35 (0.07 to 0.64) 0.02 -0.01 (-0.23 to 0.20) 0.91 
Osteophyte  0.49 (-1.07 to 2.06) 0.53 0.80 (-0.36 to 1.96) 0.18 
Osteophyte † 0.40 (-1.19 to 1.20) 0.62 0.68 (-0.49 to 1.86) 0.25 
Osteophytes†¶ 0.24 (-1.37 to 1.84) 0.77 0.67 (-0.50 to 1.84) 0.26 
Joint space 
narrowing 
0.25 (-0.33 to 0.83) 0.40 0.28 (-0.16 to 0.71) 0.21 
Joint space 
narrowing† 
0.19 (-0.37 to 0.75) 0.49 0.16 (-0.25 to 0.57) 0.44 
Joint space 
narrowing†¶ 
0.28 (-0.43 to 0.69) 0.65 0.15 (-0.26 to 0.56) 0.46 
Patellofemoral 
OA 
-0.56 (-2.21 to 1.10) 0.51 1.26 (0.04 to 2.47) 0.04 
Patellofemoral 
OA† 
-0.46 (-2.12 to 1.20) 0.59 1.11 (-0.11 to 2.32) 0.07 
Patellofemoral 
OA†¶ 
-0.56 (-2.25 to 1.13) 0.51 1.11 (-0.11 to 2.32) 0.07 
KL grade 0.17 (-0.42 to 0.75) 0.58 0.32 (-0.11 to 0.75) 0.15 
KL grade† 0.10 (-0.46 to 0.66) 0.72 0.21 (-0.20 to 0.63) 0.32 
KL grade†¶ 0.06 (-0.51 to 0.63) 0.83 0.21 (-0.21 to 0.62) 0.33 
†Adjusted for age, sex, BMI and ¶ for bisphosphonates. 589 
 590 
 591 
 592 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
31 
 
Table V 593 
Relationship of baseline serum biomarkers to change in OA pain 594 
 TRAcP5b Cathepsin K 
 β (95% CI) P β (95% CI) P 
WOMAC pain change -1.44 (-3.23 to 0.34) 0.11 0.33 (-1.03 to 1.67) 0.63 
WOMAC pain change†¥ 0.71 (-0.90 to 2.33) 0.38 0.29 (-0.83 to 1.40) 0.61 
WOMAC pain change†¥¶ 0.72 (-0.90 to 2.35) 0.38 0.30 (-0.85 to 1.45) 0.61 
NHANES I pain change 0.46 (-0.08 to 1.0) 0.10 -0.09 (-0.50 to 0.33) 0.69 
NHANES I pain change†¥ 0.69 (0.19 to 1.20) 0.008 0.02 (-0.36 to 0.41) 0.91 
NHANES I pain change†¥¶ 0.67 (0.16 to 1.18) 0.01 0.07 (-0.33 to 0.47) 0.73 
†Adjusted for baseline age, sex, BMI, and ¥ for baseline pain score (e.g. change in WOMAC 595 
pain adjusted for baseline WOMAC pain), and ¶ for bisphosphonates. Change scores are 596 
follow up scores minus baseline scores. Mean ± SD baseline WOMAC and NHANES I pain 597 
= 5.2 ± 3.2 and 2.9 ± 1.2 respectively. Mean ± SD follow-up WOMAC and NHANES I pain 598 
= 5.4 ± 4 and 2.6 ± 1.5 respectively. NHANES I pain marginal effect sizes (fold increase in 599 
TRAcP5b associated with 1 unit greater NHANES I pain score increase between baseline and 600 
follow up); 11.0, †¥5.3, †¥¶5.6 601 
 602 
 603 
 604 
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